The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Tecvayli (teclistamab-cqyv) on 2024-11-22. This approval specifically pertains to an efficacy supplement, indicating an update to the drug's approved therapeutic profile.
Background
The supplemental application for Tecvayli (teclistamab-cqyv) was submitted by Janssen Biotech. This approval specifically addresses an efficacy update for the drug, categorized as an efficacy class supplement.
What this means
This supplemental efficacy approval for Tecvayli (teclistamab-cqyv) indicates an update to the drug's approved therapeutic profile. While the specific details of the updated efficacy are not provided in the current data, such approvals generally reflect new clinical evidence supporting an expanded indication, a new patient population, or an enhancement to existing efficacy claims. Clinicians and researchers should refer to the updated prescribing information and official FDA documents for the precise nature and implications of this efficacy supplement.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 761291 S-9, an efficacy supplement for Tecvayli (teclistamab-cqyv), was recorded on 2024-11-22 on accessdata.fda.gov.